New trisubstituted purine derivatives as potent inhibitors and PROTAC warheads against mutated Bcr-Abl and Btk: A combined strategy to target key proteins for the treatment of leukaemia
Más información
Fecha de publicación: | 2023 |
Objetivos: | This research is focused on the development and optimisation of novel purine derivatives targeting two kinases involved in leukaemia, from design, in vitro biological study to in vivo assays. |
Instrumento: | FONDECYT |
Año de Inicio/Término: | 2023-2026 |
Financiamiento/Sponsor: | CONICYT |
Rol del Usuario: | COINVESTIGADOR(A) |
DOI: |
1231199 |